Medical Imaging Biochemical Markers Clinical Research Centers
About Synarc Synarc Experts News & Events
 
     
     
     
   
     
     
  
 
     
 

Ivo Valter, M.D.
Managing Director of Synarc’s Center for Clinical and Basic research in Tallinn, Estonia.


Ivo Valter, MD is the Managing Director of Synarc’s Center for Clinical and Basic research in Tallinn, Estonia. He is responsible for the overall operations of the research facility and serves as the principal investigator in studies in the field of rheumatology, internal medicine and women’s health. Dr. Valter has over 15 years of experience in patient care and clinical research. He has published several scientific articles and abstracts on these topics. Dr. Valter was a postdoctoral fellow at the Medical University of South Carolina (MUSC), Department of Medicine Division of Rheumatology and Immunology & College of Graduate Studies. He is certified by the State Agency of Medicines in ICH GCP.   
 
 

Scientific Publications:

Maricq HR, Weinrich MC, Valter I, Palesch YY, Maricq JG: Digital vascular Responses in Subjects with Cold Sensitivity, primary Raynaud's phenomenon, or Scleroderma Spectrum Disorders. J Rheumatol 1996;23:2068-78

Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Palesch Y, Biro C, Vionnet-Fuasset M, Jiguet M, Valter I: Geographic Variation in the Prevalence of Raynaud's Phenomenon: a Five Region Comparison. J Rheumatol 1997;24:879-89

Valter I, Maricq HR: Prevalence of Raynaud Phenomenon in Tartu and Tartumaa, Southern Estonia. Scand J Rheumatol 1997;26:117-24

Valter I, Saretok S, Maricq HR: Prevalence of Scleroderma Spectrum Disorders in the General Population of Estonia. Scand J Rheumatol 1997;26:419-25

Valter I, Maricq HR: Prevalence of Raynaud Phenomenon in 2 ethnic groups in the General Population of Estonia. J Rheumatol 1998;25:697-702

Palesch Y, Maricq HR, Carpentier PH, Valter I: Association between Cigarette and Alcohol Consumption and Raynaud′s Phenomenon. J Clin Epidemiol 1999;52:321-8

Maricq HR, Valter I, Maricq JG: An objective method to estimate the severity of Raynaud Phenomenon: digital blood pressure response to cooling. Vasc Med 1999;3:109-13

The Raynaud¢s Treatment Study Investigators: Comparison of Nifedipine and Temperature Biofeedback for Primary Raynaud¢s Phenomenon: Results of the Raynaud Treatment Study (RTS). Lancet 2000;

Maricq HR, Jennings JR, Valter I, Frederick M, Thompson B, Hill R: Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Vasc Med 2000.

Maricq HR,Valter I : Classification of Scleroderma Spectrum Disorders: a proposal and the results of its application to a sample of patients. Clin Exp Rheumatol 2004; 22 (Suppl. 33): S5-13.
(abstracts)

Valter I, Maricq HR: Prevalence of Raynaud phenomenon in Estonia. A preliminary report. Arthritis Rheum 1993;36(Suppl):S194

Valter I, Smith EA, Maricq H: Prevalence of Scleroderma Spectrum Type Capillary Abnormalities among Volunteers for a Raynaud Treatment Trial. Arthritis Rheum  1994; 37(Suppl):R26

Valter I, Maricq HR: Prevalence of Raynaud phenomenon in Tartumaa, Estonia. Arthritis Rheum 1995;38 (Suppl):R28

Valter I, Maricq HR: Prevalence of Scleroderma Spectrum Disorders among Estonians in Tartumaa, Southern Estonia. Arthritis Rheum 1995;38(Suppl):S333

Valter I, Maricq HR: Prevalence of Scleroderma Spectrum Disorders  in the General Population of Estonia. Arthritis Rheum 1996;39 (Suppl):S150

Valter I, Maricq HR: Risk factors associated with Raynaud Phenomenon in the general population of Estonia. Arthritis Rheum 1997;40 (Suppl):S255
Site Map     Legal Statement     © Copyright 2008 Synarc Inc.